Sign In
Buy RANI
$1.94
+0.0600 (+3.19%)
At Close: Nov 17, 2025
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
04:30pm, Thursday, 06'th Nov 2025
– Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics –
Rani Therapeutics Sees Unusually Large Options Volume (NASDAQ:RANI)
01:18am, Wednesday, 05'th Nov 2025
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI - Get Free Report) was the target of some unusual options trading on Tuesday. Investors bought 45,351 call options on the company. This is an increase of
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
08:00am, Thursday, 30'th Oct 2025
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors
04:05pm, Thursday, 23'rd Oct 2025
SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
04:01pm, Thursday, 23'rd Oct 2025
Financing led by Samsara BioCapital, L.P. (“Samsara”) with participation from additional investors, including RA Capital Management, Anomaly, Special Situations Funds, Invus and Mr.
Rani Therapeutics: Initiating At Buy On Promising RaniPill Advancement With Chugai
02:20pm, Monday, 20'th Oct 2025
Rani Therapeutics is initiated at a Buy rating, driven by major pipeline advancements and strong partnership momentum. RANI secured a $1.085 billion collaboration with Chugai Pharmaceutical, leveragin
This BlackRock and Vanguard penny stock just exploded 250%; Time to buy?
05:00am, Monday, 20'th Oct 2025
Rani Therapeutics Holdings (NASDAQ: RANI) shocked the stock market on Friday as its shares soared 248% to close at $1.64, following a collaboration with Japan's Chugai Pharmaceutical.
Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma
07:48am, Friday, 17'th Oct 2025
Rani Therapeutics said on Friday it has agreed a deal to license an oral drug to Japan's Chugai Pharmaceutical , with an option to extend it to up to five drugs, potentially bringing the total deal va
Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules
07:31am, Friday, 17'th Oct 2025
SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
SAN JOSE, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani (RANI) Q2 Net Loss Improves 16%
04:35pm, Thursday, 07'th Aug 2025
Rani Therapeutics (RANI -3.04%), a biotech company developing oral biologic drug delivery technology, released its earnings for the second quarter of fiscal 2025 on August 7, 2025. Marking an improvem
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
04:05pm, Thursday, 07'th Aug 2025
– Announced strategic research collaboration with Chugai for two undisclosed molecules – – Presented preclinical data demonstrating bioequivalence of novel, bispecific GLP-1/GLP-2 receptor agoni
Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering
09:00am, Tuesday, 15'th Jul 2025
SAN JOSE, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the ora
Rani Therapeutics Announces Research Agreement with Chugai
08:00am, Monday, 19'th May 2025
- Research agreement is evaluating feasibility of applying Rani's oral delivery technology to Chugai's antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani
